PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

Summary

This phase II trial studies how well PAT-1251 works in treating patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocytosis myelofibrosis. PAT-1251 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2019-07-24

Primary completion

2019-07-24

Completion

2019-07-24

Outcome

Outcome not reported

Stopped: “"Company is in a process of being taken over by another pharma and the new one has different ideas on how to pursue studies with this drug"”

Drugs

Indications